PIK3CD and cancer: The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, affecting 30–50% of malignancies, making it a rational and important target for innovative anticancer drug development and precision medicine [1, 2].